Cargando…
Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer
In 1960s, cromolyn sodium (CS) has been introduced as the first non-steroidal anti-inflammatory drug for the treatment of allergic and mast-cell driven diseases. Its applicability has been limited due to a poor bioavailability. Here we present pharmacokinetic data of a novel high concentration formu...
Autores principales: | Abd-Elaziz, Khalid, Oude Elberink, Hanneke, Diamant, Zuzana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480408/ https://www.ncbi.nlm.nih.gov/pubmed/32944204 http://dx.doi.org/10.1080/20018525.2020.1809083 |
Ejemplares similares
-
In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018) -
Extended Pharmacopeial Characterization of Surfactant Aerosols Generated by a Customized eFlow Neos Nebulizer Delivered through Neonatal Nasal Prongs
por: Bianco, Federico, et al.
Publicado: (2020) -
In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
por: Ohar, Jill A., et al.
Publicado: (2020) -
Effects of cromolyn sodium on isolated rat's trachea
por: Lin, Yuan-Yung, et al.
Publicado: (2011) -
Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)